Skip to main content

Novo Holdings — Portfolio, Page 3

Investor actively backing innovative startups and growth-stage companies across various industries and funding rounds.

216
Companies
$15.2B
Total invested
$84.4M
Avg. check
30
Industries
Biotechnology 15Health Care 13Therapeutics 9Medical 8Pharmaceutical 8Life Science 4+24 more
Founder contacts

Verified emails & LinkedIn for founders across this portfolio.

jane@on●●●●●●●.com
linkedin.com/in/●●●●●●
Verified contacts, updated monthly
Get instant access →

Portfolio companies

Showing 4972 of 216
Avalyn Pharma
July 2025

Avalyn Pharma is a biopharma company developing therapies for the treatment of idiopathic pulmonary fibrosis and other respiratory diseases.

Biopharma · Seattle$100.0M Series D
GlycoEra
May 2025

GlycoEra is a biotechnology research company that produces extracellular protein degraders for the treatment of autoimmune diseases.

Biotechnology · Schlieren$130.0M Series B
Reunion Neuroscience
May 2025

Reunion Neuroscience is a clinical-stage pharmaceutical company developing therapeutic solutions for underserved mental health conditions.

Biotechnology · Toronto$68.9M Venture - Series Unknown
HepaRegeniX
April 2025

HepaRegeniX is developing drugs for treating acute and chronic liver diseases.

Biotechnology · Ulm$24.3M Venture - Series Unknown
Sparrow Quantum
April 2025

Sparrow Quantum develope and commercializes photonic quantum chip technology.

Manufacturing · Copenhagen$24.2M Series A
Tribune Therapeutics
March 2025

Tribune Therapeutics specializes in building promising pipeline of novel medicines to treat patients with a wide range of fibrotic diseases.

Biotechnology · Stockholm$24.8M Series A
Callio Therapeutics
March 2025

Callio Therapeutics develops next-generation, multi-payload antibody-drug conjugates (ADCs).

Biotechnology · Seattle$187.0M Series A
Newleos Therapeutics
February 2025

Newleos Therapeutics is a biotech startup dedicated to producing safer and more effective neuroscience medicines.

Biotechnology · Boston$93.5M Series A
Commit Biologics
January 2025

Commit Biologics is a biotechnology research company developing a novel immunotherapy platform for the treatment of cancer.

Biotechnology · Aarhus$5.7M Seed
Numab
January 2025

Numab is a biotechnology company that offers antibody-based therapeutics for the treatment of severe diseases.

Biopharma · Wadenswil$54.9M Series C
Orbis Medicines
January 2025

Orbis Medicines is a novel macrocyclic chemistry and computational platform for oral macrocycle drug discovery.

Health Care · Frederiksberg$93.2M Series A
Nuvig Therapeutics
December 2024

Nuvig Therapeutics is a biotechnology company developing therapies to induce natural mechanisms to restore immune homeostasis.

Biotechnology · Redwood City$161.0M Series B
Convergent Therapeutics
September 2024

Convergent Therapeutics is a pharmaceutical company that focuses on developing radiopharmaceutical therapies for prostate cancer.

Health Care · Cambridge$40.0M Series A
Reduced
September 2024

Reduced develops natural flavor enhancers from upcycled produce.

Food and Beverage · Copenhagen$8.9M Series A
Kebotix
August 2024

Kebotix is a high-tech materials discovery and production company that reinvent the discovery of new materials using AI.

Artificial Intelligence (AI) · Cambridge$5.0M Venture - Series Unknown
Draupnir Bio
July 2024

Draupnir Bio is developing a new type of cholesterol-lowering medicine which prevents blood clots in the heart.

Biotechnology · Risskov$13.2M Seed
Myricx Bio
July 2024

Myricx Bio is a biotechnology company that develops novel NMT inhibitor payloads for ADCs to treat cancer.

Biotechnology · London$115.3M Series A
CIRCTEC
May 2024

CIRCTEC is an innovator and operator of pyrolysis technology to recycle waste into renewable fuels and circular chemicals.

Manufacturing · London$162.8M Venture - Series Unknown
Bluejay Therapeutics
May 2024

Bluejay Therapeutics is a private biopharmaceutical company focused on the development of cures for infectious diseases.

Biotechnology · San Mateo$182.0M Series C
Asgard Therapeutics
March 2024

Asgard Therapeutics is a Biotechnology Company.

Biotechnology · Lund$32.6M Series A
Octave
February 2024

Octave provides mental health care that's both accessible to people and sustainable for providers.

Health Care · San Francisco$5.0M Venture - Series Unknown
Nalu Medical
January 2024

Nalu Medical is a medical technology company that develops innovative solutions for patients with chronic neuropathic pain.

Health Care · Carlsbad$85.0M Series E
Hoba Therapeutics
December 2023

Hoba Therapeutics is developing a new therapeutic protein for the treatment of neuropathic pain.

Biotechnology · Copenhagen$24.8M Series A
Doctor Anywhere
December 2023

Doctor Anywhere is a telehealth company .

Health Care · Singapore$40.8M Series C

Where Novo Holdings invests

Biotechnology15
Health Care13
Therapeutics9
Medical8
Pharmaceutical8
Life Science4

About Novo Holdings's portfolio

How many companies has Novo Holdings invested in?

Novo Holdings has invested in 216 companies tracked in our database. The portfolio spans multiple industries and funding stages, from seed-stage startups to late-stage companies.

What industries does Novo Holdings invest in?

Novo Holdings's top investment sectors include Biotechnology, Health Care, Therapeutics, Medical, Pharmaceutical. The firm invests across 30 different industry categories.

What is Novo Holdings's largest investment?

Among tracked funding rounds, Callio Therapeutics received $187.0M in a Series A round. Novo Holdings's total known invested capital is $15.2B.

What is the average investment size for Novo Holdings?

Novo Holdings's average investment size is $84.4M across its portfolio of 216 companies.

What are Novo Holdings's most recent investments?

Recent Novo Holdings portfolio additions include Avalyn Pharma, GlycoEra, Reunion Neuroscience, HepaRegeniX, Sparrow Quantum. These companies were founded in 2020 or later.

Reach the founders behind these 216 companies
Verified emails and LinkedIn profiles, updated monthly.
Get instant access →